Crescita Therapeutics, Inc. (CTX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Crescita Therapeutics, Inc.

Æterna Zentaris, Inc.

Medicure, Inc.

Valeo Pharma, Inc.

Avricore Health, Inc.

PharmaTher Holdings Ltd.

Resverlogix Corp.

PreveCeutical Medical, Inc.

Revive Therapeutics Ltd.

Core One Labs, Inc.

XORTX Therapeutics, Inc.

Why is Crescita Therapeutics, Inc. ?

With a growth in Net Sales of 52.47%, the company declared Very Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at CAD 1.29 MM
RAW MATERIAL COST(Y) Fallen by -18.3% (YoY)
DEBTORS TURNOVER RATIO(HY) Highest at 8.87%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -22.13%, its profits have risen by 52.4%

Below par performance in long term as well as near term

Along with generating -22.13% returns in the last 1 year, the stock has also underperformed S&P/TSX 60 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Crescita Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Crescita Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Crescita Therapeutics, Inc.

-18.18%

0.31

46.99%

S&P/TSX 60

20.39%

1.54

14.62%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.27%

EBIT Growth (5y)

-2.73%

EBIT to Interest (avg)

-0.90

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.54

Sales to Capital Employed (avg)

1.06

Tax Ratio

0.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.23%

ROE (avg)

2.50%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.56

EV to EBIT

-0.55

EV to EBITDA

-1.06

EV to Capital Employed

0.13

EV to Sales

0.05

PEG Ratio

Dividend Yield

ROCE (Latest)

-24.27%

ROE (Latest)

-9.11%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 1.29 MM

RAW MATERIAL COST(Y)

Fallen by -18.3% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 8.87%

NET SALES(Q)

At CAD 6.23 MM has Grown at 52.47%

OPERATING PROFIT(Q)

Highest at CAD 0.94 MM

OPERATING PROFIT MARGIN(Q)

Highest at 15.02 %

PRE-TAX PROFIT(Q)

Highest at CAD 0.82 MM

NET PROFIT(Q)

Highest at CAD 0.82 MM

EPS(Q)

Highest at CAD 0.04

-1What is not working for the Company

CASH AND EQV(HY)

Lowest at CAD 16.72 MM

Here's what is working for Crescita Therapeutics, Inc.

Operating Cash Flow

Highest at CAD 1.29 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Pre-Tax Profit

At CAD 0.82 MM has Grown at 188.36%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CAD MM)

Net Profit

At CAD 0.82 MM has Grown at 188.12%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Net Sales

At CAD 6.23 MM has Grown at 52.47%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Operating Profit

Highest at CAD 0.94 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

Operating Profit Margin

Highest at 15.02 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CAD 0.82 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CAD MM)

Net Profit

Highest at CAD 0.82 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

EPS

Highest at CAD 0.04

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CAD)

Debtors Turnover Ratio

Highest at 8.87%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -18.3% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Crescita Therapeutics, Inc.

Cash and Eqv

Lowest at CAD 16.72 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents